These are the stocks posting the largest moves before the bell.Market Insiderread more
"My sense was we've added accommodation and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Corporate profits posted modest growth in the second quarter as companies brace for slowing global growth.Retailread more
Democratic candidates face an August 28 deadline to qualify for the September debate.2020 Electionsread more
Experts believe a wider spat with Europe would be much more damaging than the current tit-for-tat with China.Traderead more
Software stocks are the place to be in tech as the sector mounts a recovery from its recent pullback, some analysts say.Trading Nationread more
After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Dow to rise; bond yields tick higher; Fed may be behind the curve; China warns US on trade; and this weekend's G-7 summit seems doomed for failureMarketsread more
Markets pay particular attention to Italy's spending, given its public debt pile. This stands at above 130% of its growth rate, one of the highest in the world.Politicsread more
Office phones, printers, building control systems and more — these may not sound like computers but they can all be hacked according to cybersecurity pros.Technologyread more
Sometimes a spec stock turns out to be more right than even Cramer imagined.
That's certainly the case with NPS Pharma, an orphan drug maker, whose stock has exploded.
When Cramer talked with the CEO on Mad Money early in the year he noted the potential. At the time said the stock seemed cheap in light of the promising pipeline. "I think we may be looking a real opportunity," he said on January 7th. (Click here to go to Cramer: Real Opportunity in This Drug Maker)
How right Cramer was.
As it turned out, "NPS had some incredible success with its lead drug, Gattex for short-bowel syndrome, a rare condition where the intestines can't properly absorb nutrients and patients must therefore be fed through a tube, intravenously, for 12 hours a day."
Cramer said the drug has been so effective that some patients who take Gattex can go off the IV all together. This drug allows their bodies to process food once again.
Because the condition is rare, the drug is expensive.
"Gattex costs $295,000 a year for a single patient," Cramer said. And those patients will probably be taking it every year for the rest of their lives."
Largely Gattex is behind the stock's advance. "So far, as of the second quarter, NPS has sold 318 prescriptions," Cramer said.
But that's not the only catalyst going for NPS. Cramer sees more promising therapies in the pipeline.
Specifically, the Mad Money host is watching developments involving Natpara, a treatment for hypo-parathyroidism, a condition in which low levels of calcium in the blood cause severe muscle cramping, twitching and muscular spasms.
"Natpara could potentially receive FDA approval by the middle of next year," Cramer said.
"We believe the opportunity for Natpara could be even greater than Gattex," revealed Dr. Francois Nader, the CEO of NPS Pharma during an exclusive conversation with Jim Cramer on Mad Money. "And we have a pipeline that will follow that."
Read More from Mad Money with Jim Cramer
Dow changes speak volumes: Cramer
Portfolio building BRIC showing potential
At $80, UA expensive or too cheap?
All told, it would seem the drug maker's stock should have room to run. However, if you established a position earlier in the year on Cramer's recommendation, the Mad Money host suggests taking some profits.
"After that kind of move, you're being way too greedy if you don't ring the register on at least some of your position, say half or two-thirds. I think you can continue to speculate, just do it with the house's money. "
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com